Basal-like breast cancer is an aggressive subtype of mammary carcinoma. Despite expressing basal markers, typical of mammary stem cells, this tumor has been proposed to originate from luminal progenitors, which are downstream of stem cells along the mammary epithelial hierarchy. This suggests that committed luminal progenitors may reacquire basal, stem-like characteristics, but the mechanisms that regulate this transition remain unclear. Using mouse models, we found that luminal progenitors express high levels of the Met receptor for hepatocyte growth factor (HGF), as compared with the other mammary epithelial sub-populations. Constitutive activation of Met led luminal progenitors to attain stem cell properties, including enhanced clonogenic activity in vitro and de novo ability to reconstitute mammary glands in repopulation assays in vivo. Moreover, in response to Met signaling, luminal progenitors gave rise to hyperplastic ductal morphogenesis and preferentially underwent basal lineage commitment at the expense of luminal cell-fate specification. Opposite and symmetric results were produced by systemic pharmacological inhibition of Met. Hence, Met signaling targets luminal progenitors for expansion, impairs their differentiation toward the mature luminal phenotype and enables their commitment toward the basal lineage. These results emphasize a critical role for Met in promoting deregulated proliferation and basal plasticity of normal luminal progenitors in the mammary gland, a complex of events that may be required for sustaining the functional and phenotypic properties of basal-like breast tumors.
INTRODUCTION
The mammary gland contains two mature epithelial cell types, the outer basal cells and the inner luminal cells. The basal layer includes a large fraction of myoepithelial cells with specialized contractile functions and a small sub-population of stem cells. [1] [2] [3] [4] The luminal cells comprise different classes of progenitors as well as differentiated hormone-sensing elements. 5 The mammary gland is organized in a hierarchical manner, with stem cells giving rise to differentiated epithelium through a series of committed intermediates. 2, [6] [7] [8] [9] The prevailing view implies a sequence of progressive restrictions, which leads to irreversible cell-fate decisions: multipotent or lineage-restricted stem cells originate progenitors deprived of self-renewal capacity, whose descendants will undergo terminal differentiation toward either the myoepithelial or luminal epithelial compartments. 10, 11 Breast cancer is a constellation of heterogeneous diseases that are currently classified into at least six clinically relevant subtypes on the basis of gene expression profiling. [12] [13] [14] These subtypes can be roughly grouped into 'basal' or 'luminal' categories because of their molecular similarity to the basal or luminal components of the normal mammary gland. For example, basal-like breast cancers (BLBCs) express high levels of basal cytokeratins (5/6, 14, and 17) and, in some cases, display increased positivity for myoepithelial-specific markers (such as p63 and a-smooth muscle actin (aSMA)), whereas luminal-type breast cancers feature high expression of luminal markers (such as estrogen receptor and cytokeratins 8/18). 15, 16 As a result of these phenotypic differences, it was suggested that aggressive BLBCs originate from basal stem cells whereas less aggressive luminal-like tumors arise in more differentiated luminal progenitors. 15, 17 However, recent findings have questioned the model whereby mammary epithelial cells obey a linear hierarchy of differentiation programs, especially in cancer. Preneoplastic tissue of subjects harboring germline mutations of the breast cancer susceptibility gene BRCA1, who suffer a higher risk of developing BLBC, 18 shows an expansion of luminal progenitors, and molecular profiling indicates that BLBCs are more similar to normal luminal progenitors than any other epithelial sub-population, including the basal, stem-cell-enriched subset. 19 Similarly, mouse models with targeted deletion of BRCA1 specifically in luminal progenitors develop tumors that show an increase in the proportion of luminal progenitors, have basal/stem cell-like histopathological profiles and exhibit transcriptional signatures that resemble those of normal luminal progenitor cells. 20 Together, these results lend support to a previously unanticipated plasticity of luminal progenitors: most likely, this sub-population is not irreversibly committed to feed-forward terminal maturation but can alter its differentiation programs for acquisition of at least some basal/ stem cell characteristics.
The molecular mechanisms underlying the differentiation versatility of mammary luminal progenitors and their contribution to the onset of the transformed phenotype are substantially unknown. To characterize signals potentially involved in these processes, we interrogated published breast cancer expression datasets for molecules preferentially expressed in basal-type mammary tumors. 21 Data mining revealed that BLBC expression profiles are enriched for gene sets that are also over-represented in transcriptional signatures regulated by the HGF/Met ligand/receptor couple. [22] [23] [24] [25] Furthermore, according to tissue microarray analyses, Met immunoreactivity appears to be higher in BLBCs than in other tumor types. 23, 24, 26 Finally, transgenic and knock-in mouse models harboring mutationally activated forms of Met frequently develop mammary tumors, some of which display basal features. 23, 24 On the basis of all these findings, we have investigated the role of Met in the proliferation, morphogenesis and differentiation potential of mammary epithelial cells by constitutive activation of the pathway and by pharmacological Met inhibition.
RESULTS
Constitutive activation of Met in the mammary gland leads to hyperplastic ductal side branching and enhances the frequency of mammary repopulating units Total primary mammary epithelial cells were collected and fluorescence-activated cell sorting (FACS) sorted to eliminate stromal and blood cell components (Supplementary Figure 1A) . Epithelial cells were infected in suspension with high-titer lentiviral vectors encoding the Met ligand HGF (or mock empty vectors) and then transplanted into the cleared fat pads of syngeneic mice. Eight weeks post transplantation, mammary outgrowths were collected and processed for histological and molecular analysis. This procedure established a gain-of-function model in which epithelial cells secreted HGF into the surrounding fat pad, which led to constitutive Met activation through both autocrine mechanisms and a paracrine 'bystander' effect on neighboring cells. We decided to induce ectopic activation of Met by exogenous introduction of HGF rather than by enforced Met expression to avoid clonal variations in kinase activity. As a control for infection efficiency, a small amount of the infected cells were kept in culture and the supernatant was evaluated for the presence of secreted HGF by enzyme-linked immunosorbent assay; HGF expression was also assessed by quantitative real-time polymerase chain reaction (qRT-PCR) in the post-explant cells: in both cases, transduced cells expressed and secreted considerable amounts of HGF (Figure 1a) .
On whole mount morphological inspection, the outgrowths derived from HGF-transduced cells exhibited increased and disorganized side branching of the ductal tree (Figure 1b) . Closer histological scrutiny and morphometric quantitation revealed a significantly higher number of ducts that were lined by a multilayered epithelium partially obliterating the lumens, indicative of a hyperplastic phenotype (Figure 1c ). Sectioning through ducts in HGF-overexpressing outgrowths indicated the presence of actively dividing cells (as assessed by Ki67 staining) that expanded into the lumens (Figure 1d ). Consistent with Mettriggered induction of mitogenesis, the major signaling pathways involved in Met-dependent proliferation-namely, the RAF-MEK-ERK cascade and the PI3K-AKT-mTor axis 27, 28 -proved to be active in HGF-expressing outgrowths: in situ examination of explanted glands demonstrated increased phosphorylation of ERK and of the PI3K distal effector S6 (Supplementary Figure 2A) .
We then analyzed whether this phenotype was accompanied by an increase in the frequency of stem cells. Transplantation of limiting dilutions of mammary epithelial cells into cleared mammary fat pads revealed a threefold increase in the absolute number of mammary repopulating units (MRUs) for HGF-expressing glands compared with those from controls (mock, repopulating frequency 1/2271; 95% confidence intervals 1/3652-1/1412; HGF, repopulating frequency 1/723; 95% confidence intervals 1/1270-1/412; Po0.01; Figure 2a ). Moreover, ductal growth was greatly enhanced by Met constitutive activation (Figure 2b ): the extent of fat pad filling (Figure 2c ) and the number of branches ( Figure 2d ) were higher for the glands deriving from HGFtransduced cells with respect to those derived from mock cells.
Mammary morphogenesis is partially impaired by individual inhibition of Met As well as exploring the consequences of Met hyperactivation, we also assessed the effects of Met chronic inhibition on mammary gland development in vivo. To address this issue, we transplanted recipient animals with freshly sorted mammary epithelial cells and immediately started systemic treatment with an orally bioavailable small molecule inhibitor of Met (JNJ-38877605, subsequently referred to as JNJ). 29, 30 We elected to administer this compound at a daily dose of 40 mg/kg, a modality that has been shown to achieve therapeutically effective concentration in peripheral tissues and to induce complete target inhibition. [31] [32] [33] Whole mount examination of mammary explants after 8 weeks of treatment did not reveal gross differences in the morphology of glands derived from Met-inhibited mice compared with vehicletreated animals ( Figure 3a) . However, more detailed morphometric analysis indicated a statistically significant reduction in the number of ducts in JNJ-treated mice (Figure 3a ) as well as a decrease in the number of Ki67-positive proliferating cells (Figure 3b ). In line with this proliferative impairment, phosphorylation levels of ERK and S6 were reduced in JNJ-treated glands (Supplementary Figure 2B) . We did not observe evident differences in alveolar morphology between vehicletreated and JNJ-treated animals during pregnancy and lactation (Supplementary Figure 3) . Together, these results indicate that pharmacological inactivation of Met leads to a 'hypomorphic' phenotype, with a proliferative disadvantage specifically occurring in the pubertal phase of ductal branching.
We then investigated whether systemic Met blockade affected the repopulating ability of mammary stem/progenitor cells. Mice were treated with vehicle or JNJ for 8 weeks following transplantation of limiting dilutions of total mammary epithelial cells. In accordance with the results of whole mount analysis, Met inhibition produced a trend toward decreased MRU frequency, which did not reach statistical significance (vehicle, repopulating frequency 1/2998, 95% confidence intervals 1/4955-1/1815; JNJ, repopulating frequency 1/3914; 95% confidence intervals 1/6590-1/2324; P40.05; Figure 3c ). Met inhibition also affected fat pad filling, with a substantial reduction in the extent of ductal growth in JNJ-treated mice (Figure 3d and Supplementary Figure 4) .
Mammary morphogenesis is more severely impaired by concurrent inhibition of Met and EGFR We reasoned that the blunted effects produced by individual Met blockade could be due to the presence of compensatory signals that might substitute, at least partially, for interception of Met signaling in vivo. The HGF/Met system and the EGF/EGF receptor (EGFR) family members trigger superimposable signal transduction pathways 25, 34 and display complementary expression patterns in the mammary gland. While HGF is produced by mammary fibroblasts and acts on the Met receptor in epithelial cells, 35, 36 the EGFR ligands amphiregulin, EGF and TGFa reside in the ductal epithelium and elicit paracrine activation of stromal EGFR, which in turn controls branching morphogenesis and alveolar differentiation. [37] [38] [39] [40] [41] This knowledge prompted us to analyze the effects of individual versus combined inhibition of Met and EGFR. For this experiment, we decided to analyze the development of endogenous glandsrather than transplanted outgrowths-in independent cohorts of mice (n ¼ 5 mice/cohort) treated with JNJ alone, with a suboptimal concentration of the EGFR small molecule inhibitor gefitinib alone, 42, 43 or with both compounds. JNJ was administered at the conventional daily dose of 40 mg/kg. Gefitinib was administered daily at 50 mg/kg, a dose that is commonly utilized in mouse models to analyze the additive or synergistic effects of EGFR inhibition combined with other therapies. 44, 45 After drug administration from 3 to 8 weeks of age, we found that individual inactivation of either EGFR or Met exerted almost no effect on the morphology and extension of epithelial outgrowths, 
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Met signaling in mammary luminal progenitors S Gastaldi et al with glandular ducts expanding through the fat pad well ahead of the lymph node ( Figure 4 ). In contrast, when EGFR and Met were concomitantly blocked, the ducts failed to invade the fat pad and they just reached the lymph node, leading to the formation of an immature mammary gland ( Figure 4) . Overall, the extent of fat pad filling by endogenous glands was higher than that observed for transplanted outgrowths (compare, for example, Figure 4 with Figure 3a ). It is conceivable that, in transplanted outgrowths, prior organoid manipulation for isolation and sorting of the epithelial populations partially compromised cell viability and repopulating potential. Figure 1B) . The purity of the cell sub-populations was evaluated by determining expression of the luminal lineage marker cytokeratin 18 (CK18) and the basal marker cytokeratin 14 (CK14) (Supplementary Figure 5A) . Expression analysis by qRT-PCR revealed that Met was barely detectable in terminally differentiated ER þ luminal cells and poorly expressed in basal cells (Figure 5a ). Further fractionation of the basal sub-population to separate the CD49f high subset indicated no substantial enrichment of Met expression in stem cells (Supplementary Figure 5B) . Instead, Met appeared to be predominantly expressed in ER À luminal progenitors (Figure 5a ).
Met is preferentially expressed in ER
Differential expression of Met in the mammary sub-populations resulted in a different clonogenic response to HGF in Matrigel cultures. Consistent with established findings, 1,3 ER þ differentiated luminal cells failed to grow, independent of HGF treatment. In contrast, HGF stimulation strongly enhanced the clonogenic potential of ER À luminal progenitors, leading to the production of three times more colonies with a threefold increase in size (Figure 5b) . At closer inspection, the colonies formed by nonstimulated cells appeared as uniformly spherical, alveolar-like structures, in accordance with previous results 1, 3 ; conversely, colonies grown in the presence of exogenous HGF appeared as irregular-shaped multicellular bodies, similar to the solid aggregates produced by stem-cell-enriched populations 1, 3 ( Figure 5b ). In line with the lower expression levels of Met in the basal sub-population, the effect of ligand administration on this cell fraction proved to be weaker in terms of colony numbers and negligible when considering colony size (Figure 5b) .
As an additional approach to substantiate these results we carried out two-dimensional colony formation assays, in which we evaluated the formation of multicellular aggregates from ER of mammary epithelial cells and fibroblasts with the JNJ Metspecific inhibitor. After seven days of culture, Met-inhibited ER À luminal progenitors yielded substantially fewer colonies compared to untreated cells and the colonies were considerably smaller (Figure 5c ). Consistent with the notion that colony-forming ability in low-cell density adherent cultures is mainly displayed by luminal progenitors, 3 basal cells produced small-sized clonal aggregates. In line with the lower expression levels of Met in the basal sub-population (Figure 5a ), the consequences of Met inhibition on this cell fraction proved to be weak in terms of reduction of colony numbers (Figure 5d ).
Met activation endows luminal progenitors with repopulating activity in vivo
To confirm in vivo that Met activation specifically encourages the growth potential of luminal progenitors, cells from the bulk epithelial population were transduced with the mock or HGF lentiviral constructs and then implanted in recipient mice. Eight weeks post transplantation, we assessed the relative distribution of the mammary epithelial fractions by FACS analysis. Control (mock) cells appeared to be evenly distributed among the three sub-populations, with an average 31% of cells exhibiting a CD24 þ /low Sca1 À basal phenotype, 37% exhibiting CD24 þ /high Sca1 À luminal progenitors, and 32% exhibiting CD24 þ /high Sca1 þ differentiated luminal cells. In contrast, Met activation led to a higher representation of cells with a flow cytometric profile typical of luminal progenitors (52%) at the expense of the other subgroups (25% of basal cells and 23% of differentiated luminal cells) (Figure 6a) .
When purified and transplanted into cleared fat pads, the luminal ER À population is almost completely devoid of repopulating capacity. [1] [2] [3] Indeed, when we analyzed the post-transplantation outgrowths of luminal progenitors transduced with the mock construct and implanted in 10 different animals (20 000 cells/ mouse), we found that six transplants failed to colonize the fat pad and the remaining four gave rise to abortive mammary trees composed of short, rudimentary ducts (Figure 6b ). In contrast, 8 out of 10 animals implanted with luminal progenitors expressing HGF developed outgrowths that were composed of elongated ducts with properly organized ramifications (Figure 6b ). The number of ducts in HGF-expressing outgrowths was significantly higher compared with that of mock glands (Figure 6b ). We extended this observation by performing limiting dilution transplantation assays with freshly sorted ER À cells. Transduction of HGF strongly increased the ability of luminal progenitors to repopulate the fad pad, leading to an almost fourfold increase in the absolute number of repopulating cells and to a higher extent of fat pad filling (mock, repopulating frequency 1/32795; 95% confidence intervals 1/69813-1/15406; HGF, repopulating frequency 1/8679; 95% confidence intervals 1/14849-1/5073; Po0.01; Figure 6c; Supplementary Figure 6) . Together, these results indicate the Met activation targets luminal progenitors for expansion and endows them with in vivo repopulating activity.
Constitutive activation of Met in luminal progenitors affects lineage determination by funneling cell fate toward a more basal phenotype We wished to explore whether Met activation in luminal progenitors influenced not only their growth and repopulating potential, but also their cell-fate commitment. We therefore infected freshly sorted luminal progenitors with mock-or HGFexpressing vectors and transplanted them into host mice. Eight weeks post transplantation, we performed a detailed in situ appraisal of the relative distribution of mammary sub-populations using immunohistochemical markers that allow phenotypic discrimination between the basal/myoepithelial compartment and the luminal cell lineage. Besides CK14 and CK18, these include (among others) aSMA and p63 for basal cells, and ER for terminally differentiated luminal cells. Histological sectioning followed by morphometric analysis revealed a statistically significant correlation between Met activation and an increased number of cells that expressed the basal markers p63, CK14 and aSMA, together with a strong reduction in the number of cells positive for the luminal markers ER and CK18 (Figure 7 ). These findings indicate that Met constitutive activation in luminal progenitors impairs their terminal differentiation and enhances the representation of a cell compartment with basal characteristics.
We also analyzed the expression of differentiation markers in glands from mice treated with vehicle or the JNJ inhibitor. Consistent with that observed in HGF-expressing luminal progenitors, but in an opposite direction, we found that Met-inhibited mammary outgrowths had a lower number of cells positive for the basal markers p63, CK14 and aSMA, and a higher number of cells expressing the luminal markers ER and CK18 (Supplementary Figure 7) . By mirroring the results obtained in HGF-expressing glands, these pharmacological inhibition experiments solidify the notion that Met signaling opposes luminal differentiation and favors basal lineage commitment.
Met is highly expressed in basal-like murine mammary tumors arising from luminal progenitors Glands overexpressing HGF show an increase in the luminal progenitor cell fraction together with a reduction in the basal subset, according to FACS analysis ( Figure 6A) ; however, such glands exhibit basal immunohistochemical markers and are poorly positive for markers that are preferentially expressed in luminal cells (Figure 7 ). This scenario is fully recapitulated in BLBCs: indeed, these tumors feature an expansion of luminal progenitors at the expense of the basal cell compartment-as assessed by FACS sorting 19 -and display a higher representation of cells expressing markers of the basal lineage-as assessed by immunohistochemistry. 16 These analogies advocate a role for HGF/Met signaling in the tumor-related expansion of aberrant luminal progenitors with basal characteristics. We tackled this issue by analyzing Met expression in tumors deriving from a mouse model of BLBC featuring loss of BRCA1 function specifically in luminal progenitors. 20 As expected, these tumors showed a severe contraction of the subset containing CD24 þ /high Sca1 þ , ER þ differentiated luminal cells and an expanded Sca À population containing both CD24 þ /low basal cells and CD24 þ /high luminal progenitors. In such tumors, Met appeared to be intensely expressed in CD24 þ /high luminal progenitors (Figure 8) . These results are concordant with previous clinical observations indicating high expression of Met in BLBCs. 23, 24, 26 
DISCUSSION
The assembly of epithelial cells into branched tubular structures represents the structural basis for the configuration of several parenchymal organs, among which the mammary gland is one of the archetypal examples. [47] [48] [49] Using FACS-based purification of mammary epithelial sub-populations, in vivo and in vitro functional assays, and phenotypic analysis, we show here that Met, the tyrosine kinase receptor for HGF, acts as a critical regulator of luminal cell proliferation and differentiation in the context of murine mammary morphogenesis.
We provide evidence that Met is preferentially expressed in ER À luminal progenitors and that its activation by ex vivo gene transfer of HGF-specifically in this epithelial subsetstimulates clonogenic activity in vitro, confers repopulating potential in vivo and promotes aberrant branching morphogenesis. Previous in situ analyses and experiments with organotypic cultures have shown that HGF, secreted by the local mesenchyme during post-natal development, acts on the Met receptor expressed by the nearby epithelium and induces branching of mammary ducts. 35, 36 Hence, Met constitutive activation exacerbates (and deconstructs) a physiological developmental process.
We found that concomitant inhibition of Met and EGFR more severely impaired morphogenesis than inhibition of Met alone. Therefore, Met function appears to be sufficient to stimulate excessive arborization of the ductal tree, but it is not necessary: when Met is blocked, other pathways can subsidize development and maturation of the mammary gland. In line with this assumption, dual blockade of both receptors still resulted in a discernible-although less extended-glandular organization. As we used compound concentrations that are known to achieve effective target inhibition in tumor xenografts, [31] [32] [33] 44, 45 we can reasonably exclude poor pharmacokinetic or pharmacodynamic disposition of the inhibitors. More plausibly, alternative signals were still present that fostered proliferation and differentiation of the mammary gland even when Met and EGFR were both neutralized. Previous studies have demonstrated a certain degree of redundancy during mammary morphogenesis. For example, within HER family members, HER2/HER3 heterodimers mediate ductal outgrowth and elongation in response to heregulin stimulation, whereas HER4 influences lobuloalveolar differentiation. [50] [51] [52] [53] Similarly, stromal signals such as Wnt ligands and fibroblast growth factors act as paracrine cues to induce epithelial side branching. 54, 55 We also show that Met signaling restricts terminal differentiation of luminal progenitors and favors their commitment toward a more basal phenotype. The first hint that luminal progenitor cells might escape default commitment toward the mature ductal/alveolar phenotype was provided by studies in breast cancer. Both gene expression profiles in patients and experiments Met signaling in mammary luminal progenitors S Gastaldi et al in animal models have suggested a luminal progenitor origin for BLBCs, leading to the proposition that a more accurate name for this subclass of breast tumors should be the 'luminal progenitor' subtype. 17, 19, 20 The preferential expression of Met in luminal progenitors and the strong clonogenic and proliferative effects that Met pathway activation exerts on these cells, together with the observation that Met activity negatively impacts their terminal differentiation and favors the acquisition of basal markers, suggest a role for HGF/Met signaling in the tumorrelated expansion of aberrant luminal progenitors with basal characteristics. [56] [57] [58] This is in accordance with our observation that, in a mouse model of BLBC, 20 Met appears to be highly expressed in CD24 þ /high cancer cells that resemble normal luminal progenitors.
Collectively, these findings shed new light onto the mechanisms that control morphogenetic events and cell-fate decisions in the mammary gland and have important implications for the role of Met in breast tumorigenesis. 
MATERIALS AND METHODS
Mammary cell preparation, cell sorting and primary cell culture Animal procedures were approved by the Ethical Commission of IRCC (Candiolo, Italy), and by the Italian Ministry of Health. Single-cell suspensions were prepared from mammary fat pads of 10-to-12-week-old virgin female FVB mice as described. 20, 59 Cell suspensions were stained with anti-CD45-PE-Cy7 (clone 30-F11, BD Biosciences, San José , CA, USA), anti-CD24-FITC (clone M1/69, BD Biosciences), anti-Sca1-PE (clone D7, eBioscience, San Diego, CA, USA) and anti-CD49f-PE-Cy5 (clone GoH3, BD Biosciences). Cells were then resuspended in medium containing 4,6-diamidino-2-phenylindole dihydrochloride for analysis and cell sorting. Analysis and sorting were carried out using a MoFlow high speed cell sorter (Dako, Glostrup, Denmark).
For three-dimensional colony-forming assays, freshly sorted cells were plated on a layer of basement membrane matrix Matrigel (BD Biosciences) at a density of 4000 cells/well in an eight-well chamber slide (BD Biosciences). Cells were allowed to grow for 10 days in DMEM/F12 medium supplemented with 10% FCS, 5 mg/ml bovine pancreatic insulin (Sigma, St Louis, MO, USA), 10 ng/ml cholera toxin (Sigma) and 10 ng/ml EGF (Sigma). Number and size of the colonies were evaluated using Image-J. For two-dimensional colony formation assays, NIH-3T3 mouse fibroblasts were irradiated (30 Gy) and plated in a 6-well plate. The following day, 1000 freshly sorted mammary epithelial cells were plated on the fibroblast monolayer. Cells were allowed to grow for seven days and then fixed in 10% glutharaldeyde and stained with Crystal violet.
Lentiviral vectors and infections
The lentiviral vector encoding for HGF 60 was produced by lipofectAMINE 2000-mediated transient transfection of 293T cells (Invitrogen, Grand Island, NY, USA). Freshly sorted mammary epithelial cells were plated on ultralow attachment six-well plates (Corning, Corning, NY, USA) at a density of 100 000 cells/ml and then transduced with HGF or mock lentiviral vectors (100 ng viral particles/100 000 cells).
Cleared fat pad transplantation
Mammary epithelial cells sorted by flow cytometry and infected with mock or HGF-expressing lentiviral vectors were manually counted and transplanted at limiting dilution into the cleared fat pads of 3-week-old syngeneic mice as described. 1 In some experiments, mice were treated with JNJ-38877605 (40 mg/kg/day), gefitinib (50 mg/kg/day), or both. Compounds were diluted in a vehicle containing 0.5% methyl-cellulose, 0.1% Tween-80 and were administered daily by orogastric gavage, starting two days after transplantation. Fat pads were wholemounted, carmine stained and analyzed as described. 5 The amount of fat pad filled by transplanted cells was quantitated using Image-J.
Immunohistochemistry
Immunohistochemistry was carried out via standard techniques. Staining was evaluated independently by two of the authors (FS and LT) blinded to the type of genetic or pharmacological manipulation of the outgrowths and any discrepancy was resolved by a consensus review. All markers were semiquantitatively assessed by estimating the percentage of morphologically unequivocal cells displaying either nuclear (Ki67, ER and p63) or cytoplasmic (aSMA, CK14 and K18) staining. The following antibodies were used: mouse mAb anti-CK14, clone LL002 (Abcam, Cambridge, UK); mouse mAb anti-CK18, clone Ks18.04 (Progen, Heidelberg, Germany); mouse mAb anti-p63, clone 4A4 (BD Biosciences); rat mAb anti-mouse Ki67, clone TEC-3 (Dako); rabbit polyclonal anti-aSMA (Abcam); mouse mAb anti-ERa, clone 1D5 (Dako).
RNA extraction and qRT-PCR
RNA isolation was performed as described. 32 Reverse transcription was performed using the Omniscript RT kit (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. qRT-PCR was carried out with TAQMAN probes (Applied Biosystems, Carlsbad, CA, USA: Met: Mm00434924_m1; Krt14, Mm00516876_m1; Krt18, Mm01601702_g1; GAPDH, Mm99999915_g1). The results were analyzed with the D-DCt method normalized to GAPDH and compared with a comparator sample.
Statistics
Statistical analyses were performed by the two-tailed Student's t test or Chi-square test. Limiting-dilution data were analyzed with the L-calc software (StemCell Technologies, Vancouver, BC, Canada). MRU frequencies were estimated by a complementary log-log generalized linear model. Two-sided 95% Wald confidence intervals were computed. In cases of zero outgrowths, one-sided 95% Clopper-Pearson intervals were computed. For all tests, the level of statistical significance was set at Po0.05. 
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